Recovery of the human immunodeficiency virus from fiberoptic bronchoscopes

P J V Hanson, D Gor, J R Clarke, M V Chadwick, B Gazzard, D J Jeffries, H Gaya, J V Collins

Abstract

Ten bronchoscopes that had been used on patients with the acquired immunodeficiency syndrome were sampled to determine the nature and extent of microbial contamination. Samples were taken by irrigating the suction biopsy channel with modified viral transport medium and by swabbing the insertion tube. Sampling was repeated after they had been cleaned in detergent and after two minutes' disinfection in 2% alkaline glutaraldehyde. Before being cleaned the seven bronchoscopes tested by polymerase chain reaction were contaminated with the human immunodeficiency virus, though infectivity and antigen assays gave negative results. Other organisms identified were hepatitis B virus (1), commensal bacteria (9), and *Pneumocystis carinii* (4). Mean bacterial contamination was 2.27 log colony forming organisms per millilitre. Cleaning the bronchoscope before disinfection removed all detectable contaminants with a reduction in bacterial growth of up to 8 log colony forming units/ml.

The emergence of human immunodeficiency virus infection has been accompanied by a changing pattern of pulmonary infection and new indications for performing fiberoptic bronchoscopy. Concern has been expressed about the possible transmission of HIV and other serious pathogens at bronchoscopy, a risk faced both by patients and by the staff of bronchoscopy units. Although one large retrospective study found a low incidence of infectious complications of bronchoscopy,¹ there have been reports of bronchoscopic cross infection with *Mycobacterium tuberculosis*,^{2,3} *M chelonae*,⁴ *Serratia marcescens*,⁵ and *Pseudomonas aeruginosa*.^{6,4} In addition, contamination of diagnostic samples with *Bacillus* species,⁷ *Proteus*,⁸ *Pseudomonas aeruginosa*,⁹ and *M avium-intracellulare*¹⁰ has been reported. The reasons cited for persistent contamination tend to be inadequate precleaning, use of an ineffective disinfectant, and undetected damage to the internal surfaces of the bronchoscope.

Viral transmission at bronchoscopy has not been reported, though cross infection with hepatitis B virus occurred as a result of a contaminated gastroscope.¹¹ Furthermore, injudicious use of a needle to remove tissue infected with HIV and hepatitis B virus from bronchoscope biopsy forceps has caused

inoculation and infection with hepatitis B virus, though HIV was not transmitted (P Hopewell, personal communication). It is uncertain whether HIV contaminates bronchoscopes, and if so whether bronchoscopic inoculation might result in infection. The cleaning and disinfection procedures required for bronchoscopes used in patients with HIV infection have yet to be shown to be effective.

We sampled 10 bronchoscopes used on patients with the acquired immunodeficiency syndrome to identify and quantify as wide a range of contaminating microorganisms as possible. The reductions in contamination achieved with both cleaning and disinfection were measured. This small series is illustrative only: it would be necessary to sample 400 bronchoscopes to be 95% certain that effective decontamination was 99% reproducible.

Methods

SAMPLING

Ten Olympus BF10 bronchoscopes were sampled immediately after being used for diagnostic bronchoscopy on patients with pulmonary manifestations of AIDS. The suction biopsy channel was irrigated with antibiotic free viral culture medium (Eagles MEM, Gibco Ltd, Paisley, with 2% fetal calf serum and 0.24% sodium bicarbonate) and 3 ml was collected at the distal end. The surface of the insertion tube was swabbed and the swab immersed in viral medium. Samples for viral analysis were treated with 100 µg/ml amphotericin B to prevent fungal overgrowth of tissue cultures. The bronchoscope was then washed in a Keymed autodisinfectant in 0.5% neutral detergent (Applied Chemicals Ltd). Residual detergent was eluted with viral medium and sampling was repeated. The bronchoscope was disinfected in the autodisinfectant with freshly activated 2% alkaline glutaraldehyde (Cidex, Surgikos) for two minutes and rinsed in tap water, and further samples were taken.

HIV STUDIES

Three methods were used for the detection of HIV. (1) Samples were stored at -70°C and subsequently tested by the enzyme linked immunosorbent assay (ELISA) for core antigens (Abbott Diagnostic Products); (2) 1 ml aliquots were inoculated into fresh cultures of 10⁵ C8166 T lymphocytes (kindly provided by RC Gallo) in 3 ml RPMI 1640 medium with

Royal Brompton and
National Heart and
Lung Hospital, London
SW3 6HP

P J V Hanson
M V Chadwick
H Gaya
J V Collins

Westminster Hospital,
London SW1P 2AR
P J V Hanson
B Gazzard
J V Collins

St Mary's Hospital,
London W2 1PG

D Gor
J R Clarke
D J Jeffries

Reprint requests to:
Dr P J V Hanson,
Department of Medicine,
Guy's Hospital,
London SE1 9RT

Accepted 29 March 1991

20 nU anti- α -interferon (Wellcome Diagnostics, Dartford), 20 μ g/ml interleukin II, 10% fetal calf serum, and 1% penicillin, streptomycin and L-glutamine. Cultures were incubated at 37°C in 5% carbon dioxide for 28 days and examined for cytopathic changes. Culture fluid was harvested about every seven days for determination of p24 antigen by ELISA. (3) DNA was extracted from 100 μ l of each sample by the sodium dodecyl sulphate proteinase K technique. Amplification of HIV specific complementary DNA (cDNA) was performed by using the polymerase chain reaction described by Saiki *et al.*¹² The method was modified to give 35 cycles of denaturation (one minute at 94°C), annealing (one minute at 55°C), and extension (one minute at 72°C) in the presence of 200 μ M each of deoxyadenosine triphosphate, deoxycytosine triphosphate, deoxyguanosine triphosphate, and deoxythymidine triphosphate (Sigma Chemicals, Poole), with 17 base oligonucleotide primers from the p24 gag region of HTLV111 (Oswell DNA Service, Edinburgh) and 2.5 units of Taq polymerase in ionic buffer (Perkin Elmer Cetus, Norwalk, Connecticut). HTLV 1 transformed C8166 lymphocytes were used as a negative control. After amplification samples were analysed by electrophoresis on polyacrylamide gel and visualised with ethidium bromide. Southern blotting was carried out under high stringency conditions with a ³²P labelled cDNA probe derived from HTLV111b.

MICROBIOLOGICAL ANALYSIS

Samples were inoculated, diluted and undiluted, on to buffered charcoal yeast extract (for *Legionella pneumophila*), McConkey's and chocolate agar, aerobic and anaerobic blood agar, Sabaraud's medium at room and body temperature, and Lowenstein-Jensen slopes. Samples were also inoculated into Bactec radiometric medium for culture of mycobacteria. Indirect immunofluorescence tests for *Pneumocystis carinii* cysts (Northumbria Biologicals Ltd) and Grocott staining were performed. Bacterial and fungal cultures were read after two to five days' incubation and organisms quantified in colony forming units (cfu)/ml. Mycobacterial cultures were read after six weeks' incubation.

OTHER VIRAL STUDIES

Viral cultures were performed in monkey kidney cells, human embryo fibroblasts, and Vero and HEp 2 cells for cytomegalovirus, respiratory syncytial virus, adenoviruses, enteroviruses, herpes simplex virus, and myxoviruses. Immunofluorescence tests were performed on cytomegalovirus and adenovirus cultures and haemadsorption for myxoviruses. The enzyme linked immunosorbent assay (Wellcozyme, Wellcome Diagnostics, Dartford) was performed for hepatitis B virus surface antigen.

Results

The microorganisms identified are given in the table. Of the 20 areas sampled on 10 bronchoscopes, 18 were found to be contaminated immediately after use of the bronchoscope. The mean contamination of the biopsy channel was 2.3 and of the tube surface 2 log₁₀ cfu/ml. Contamination of 6 log cfu/ml or greater occurred on three bronchoscopes. HIV cDNA was detected on all seven bronchoscopes examined, though tissue culture infectivity assays and antigen immunoassays gave negative results. After the bronchoscopes had been washed in neutral detergent all sites were free of all detectable microorganisms and HIV could no longer be detected even by the polymerase chain reaction. Samples taken after subsequent disinfection for two minutes in 2% alkaline glutaraldehyde were also free of contamination.

Discussion

The bacteria identified on the 10 bronchoscopes were predominantly commensal bacteria of the respiratory tract. The extent of contamination was considerably less than has been reported in studies of gastrointestinal endoscopes, perhaps owing to the fact that the respiratory tract is more sterile than the upper digestive tract but also in part to the fact that the gastroscope has longer, narrower channels than the bronchoscope.^{13,14} Several organisms known to infect the respiratory tract in AIDS, such as mycobacteria and cytomegalovirus, were not found in this study, though they might have been found in a larger series.

The polymerase chain reaction was not available for testing samples from three bronchoscopes but it detected HIV genetic material on the other seven bronchoscopes. The site of contamination was the biopsy channel in three, the insertion tube surface in three, and both sites in one. The polymerase chain reaction amplifies specific DNA sequences by a factor of at least 10⁶ and, with Southern blotting for confirmation, can detect a specific DNA sequence in a single cell against a background of 10⁵ uninfected cells.¹² Laboratory contamination, a potential source of false positive results,¹⁵ is unlikely to have produced the pattern of positive results seen in this study as the samples were extracted under identical conditions and tested in random order. The origin of the infected cells is uncertain: HIV

Identification and quantification of bacteria and *Pneumocystis carinii* cysts on 10 bronchoscopes used for patients with AIDS

Organism	Mean (range) log cfu/ml*	No of bronchoscopes contaminated		
		Dirty	Cleaned	Disinfected†
<i>Streptococcus viridans</i>	3.64 (1.0–8.0)	8	0	0
<i>Streptococcus epidermidis</i>	2.07 (1.7–2.6)	4	0	0
<i>Pneumocystis carinii</i> *	1.18 (1.0–1.3)	4	0	0
<i>Neisseria</i> spp	3.53 (2.9–6.0)	2	0	0
<i>Staphylococcus aureus</i>	4.34 (2.7–6.0)	1	0	0
Coliform bacteria	3.00 (—)	1	0	0
HBsAg		1	0	0
HIV		7/7	0/7	0/7

*Except for *P. carinii*, where the units are cysts/ml.

†For two minutes in alkaline glutaraldehyde.

HBsAg—hepatitis B virus surface antigen.

has been isolated from alveolar macrophages,¹⁶ bronchoalveolar lavage fluid,¹⁷ and open lung biopsy tissue¹⁸ as well as blood and saliva.

Samples shown to be positive by the polymerase chain reaction did not infect tissue cultures, suggesting that the virus was present in non-infectious form or in amounts too small to be detected by tissue culture. HIV antigens could not be found on bronchoscopes with the Abbott antigen immunoassay, which measures predominantly p17 and p24 core antigens and has a sensitivity of 30 pg/ml. HIV antigenaemia correlates poorly with the presence of plasma viraemia, however, and the absence of core antigens does not exclude the presence of infectious virus.¹⁹ The infectious dose of HIV for man is not known and the presence of integrated HIV DNA on a bronchoscope recently removed from a patient with AIDS implies that the potential for cross infection exists.

Cleaning in detergent proved effective in removing all detectable contamination from bronchoscopes. Of particular note was the removal of all detectable HIV. The bacterial reductions achieved with cleaning compared favourably with the generally accepted criterion for disinfectant efficacy—that is, a 4 log unit reduction in contaminating organisms. HIV has been found to retain its infectivity at room temperature even when dried^{20,21} and is more resistant to glutaraldehyde in the presence of protein. Precleaning is therefore essential after every bronchoscopy procedure and should not be delayed until after disinfection, as has been advocated.²²

We wish to thank the Department of Health, Medical Research Council, Keymed, Surgikos, and the Sanatorium Society for financial support.

- 1 Credle W, Smiddy J, Elliott RC. Complications of fiberoptic bronchoscopy. *Am Rev Respir Dis* 1974;**109**:67–72.
- 2 Nelson KE, Larson PA, Schraufnagel DE, Jackson J. Transmission of tuberculosis by flexible fibrebroncho-

scopes. *Am Rev Respir Dis* 1983;**127**:97–100.

- 3 Leers W. Disinfecting endoscopes: how not to transmit *Mycobacterium tuberculosis* by bronchoscopy. *Can Med Ass J* 1980;**123**:275–80.
- 4 Pappas SA, Schaaff DM, Diconstanzo MB, King FW, Sharp JT. Contamination of flexible fiberoptic bronchoscopes. *Am Rev Respir Dis* 1983;**127**:391–2.
- 5 Webb SF, Vall-Spinosa A. Outbreak of *Serratia marcescens* associated with the flexible fibrebronchoscope. *Chest* 1975;**68**:703–8.
- 6 Sammartino MT, Israel RH, Magnussen CR. *Pseudomonas aeruginosa* contamination of fiberoptic bronchoscopes. *J Hosp Infect* 1982;**3**:65–71.
- 7 Goldstein B, Abrutyn E. Pseudo-outbreak of *Bacillus* species: related to fiberoptic bronchoscopy. *J Hosp Infect* 1985;**6**:194–200.
- 8 Weinstein HJ, Bone RC, Ruth WE. Contamination of a fiberoptic bronchoscope with a *Proteus* species. *Am Rev Respir Dis* 1977;**116**:541–3.
- 9 Hussain SA. Fiberoptic bronchoscope related outbreak of infection with *pseudomonas*. *Chest* 1978;**74**:483.
- 10 Dawson DJ, Armstrong JG, Blacklock ZM. Mycobacterial cross contamination of bronchoscopy specimens. *Am Rev Respir Dis* 1982;**126**:1095–7.
- 11 Birnie GG, Quigley EM, Clements GB, Follet EAC, Walkinson G. Endoscopic transmission of hepatitis B virus. *Gut* 1983;**24**:171–4.
- 12 Saiki R, Gelfand DH, Stoffel S, et al. Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. *Nature* 1988;**339**:487–91.
- 13 Hanson PJV, Gor D, Clarke JR, et al. Contamination of fiberoptic endoscopes in AIDS. *Lancet* 1989;**ii**:86–8.
- 14 Ayliffe GAJ, Babb JR, Bradley CR. The immersible endoscope. *Lancet* 1984;**ii**:161.
- 15 Lo Y-MD, Mehal WZ, Fleming KA. False-positive results and the polymerase chain reaction. *Lancet* 1988;**ii**:679.
- 16 Salahuddin SZ, Rose RM, Groopman JE, Markham PD, Gallo RC. Human T lymphotropic virus type III infection of human alveolar macrophages. *Blood* 1986;**68**:281–4.
- 17 Resnick L, Pitchenik AE, Fisher E, Croncy R. Detection of HTLVIII/LAV specific IgG and antigen in bronchoalveolar lavage fluid from two patients with lymphocytic interstitial pneumonitis associated with AIDS-related complex. *Am J Med* 1987;**82**:553–6.
- 18 Chayt KJ, Harper ME, Marselle LM, et al. Detection of HTLV III RNA in lungs of patients with AIDS and pulmonary involvement. *JAMA* 1986;**256**:2356–9.
- 19 Coombs RW, Collier AC, Allain JP, Nikora B, Leuther M, Gjerset GF, Corey L. Plasma viremia in human immunodeficiency virus infection. *N Engl J Med* 1989;**321**:1626–31.
- 20 Hanson PJV, Gor D, Jeffries DJ, Collins JV. Chemical inactivation of HIV on surfaces. *BMJ* 1989;**298**:862–4.
- 21 Resnick L, Veren K, Salahuddin SZ, Tondreau S, Markham PD. Stability and inactivation of HTLVIII/LAV under clinical and laboratory environments. *JAMA* 1986;**255**:1887–91.
- 22 Department of Health and Social Security. *Guidance for surgeons, anaesthetists, dentists and their teams in dealing with patients infected with HTLV III*. London: DHSS, 1986. (AIDS booklet 3.)